Literature DB >> 33381488

Arsenic Exposure and Cancer-Related Proteins in Urine of Indigenous Bolivian Women.

Jessica De Loma1, Anda R Gliga1, Michael Levi1, Franz Ascui2, Jacques Gardon3, Noemi Tirado4, Karin Broberg1.   

Abstract

Indigenous people living in the Bolivian Andes are exposed through their drinking water to inorganic arsenic, a potent carcinogen. However, the health consequences of arsenic exposure in this region are unknown. The aim of this study was to evaluate associations between arsenic exposure and changes in cancer-related proteins in indigenous women (n = 176) from communities around the Andean Lake Poopó, Bolivia. Arsenic exposure was assessed in whole blood (B-As) and urine (as the sum of arsenic metabolites, U-As) by inductively coupled plasma-mass spectrometry (ICP-MS). Cancer-related proteins (N = 92) were measured in urine using the proximity extension assay. The median B-As concentration was 2.1 (range 0.60-9.1) ng/g, and U-As concentration was 67 (12-399) μg/L. Using linear regression models adjusted for age, urinary osmolality, and urinary leukocytes, we identified associations between B-As and four putative cancer-related proteins: FASLG, SEZ6L, LYPD3, and TFPI2. Increasing B-As concentrations were associated with lower protein expression of SEZ6L, LYPD3, and TFPI2, and with higher expression of FASLG in urine (no association was statistically significant after correcting for multiple comparisons). The associations were similar across groups with different arsenic metabolism efficiency, a susceptibility factor for arsenic toxicity. In conclusion, arsenic exposure in this region was associated with changes in the expression of some cancer-related proteins in urine. Future research is warranted to understand if these proteins could serve as valid biomarkers for arsenic-related toxicity.
Copyright © 2020 De Loma, Gliga, Levi, Ascui, Gardon, Tirado and Broberg.

Entities:  

Keywords:  Andes; Bolivia; FASLG; TFPI2; arsenic; biomarker; carcinogenic

Mesh:

Substances:

Year:  2020        PMID: 33381488      PMCID: PMC7767847          DOI: 10.3389/fpubh.2020.605123

Source DB:  PubMed          Journal:  Front Public Health        ISSN: 2296-2565


  71 in total

Review 1.  Measurement of urinary concentration: a critical appraisal of methodologies.

Authors:  V Chadha; U Garg; U S Alon
Journal:  Pediatr Nephrol       Date:  2001-04       Impact factor: 3.714

2.  Proteomic profiling in the sera of workers occupationally exposed to arsenic and lead: identification of potential biomarkers.

Authors:  Rihong Zhai; Suhua Su; Xin Lu; Ruiqing Liao; Xianmin Ge; Min He; Yuanjiao Huang; Sui Mai; Xi Lu; David Christiani
Journal:  Biometals       Date:  2005-12       Impact factor: 2.949

3.  Pattern of expression of apoptosis and inflammatory genes in humans exposed to arsenic and/or fluoride.

Authors:  Mariana Salgado-Bustamante; María D Ortiz-Pérez; Emma Calderón-Aranda; Lizbeth Estrada-Capetillo; Perla Niño-Moreno; Roberto González-Amaro; Diana Portales-Pérez
Journal:  Sci Total Environ       Date:  2009-12-04       Impact factor: 7.963

4.  Elevated Expression of LYPD3 Is Associated with Lung Adenocarcinoma Carcinogenesis and Poor Prognosis.

Authors:  Ping Hu; Ying Huang; Yuanyuan Gao; Hui Yan; Xiaoge Li; Jiao Zhang; Yan Wang; Yanjiao Zhao
Journal:  DNA Cell Biol       Date:  2020-02-10       Impact factor: 3.311

Review 5.  Apoptosis Markers in Breast Cancer Therapy.

Authors:  Charushila Y Kadam; Subodhini A Abhang
Journal:  Adv Clin Chem       Date:  2016-01-19       Impact factor: 5.394

Review 6.  Mechanisms of arsenic biotransformation.

Authors:  Marie Vahter
Journal:  Toxicology       Date:  2002-12-27       Impact factor: 4.221

7.  Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer.

Authors:  Qiao Zhang; Yao Zhang; Shi Z Wang; Ning Wang; Wei G Jiang; Yao H Ji; Shu L Zhang
Journal:  J Exp Clin Cancer Res       Date:  2012-01-02

8.  Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells.

Authors:  Yingjian Zeng; Guangyang Weng; Jiaxin Fan; Zhangqiu Li; Jianwei Wu; Yuanming Li; Rong Zheng; Pingfang Xia; Kunyuan Guo
Journal:  Oncol Rep       Date:  2016-07-15       Impact factor: 3.906

Review 9.  The Association of Arsenic Metabolism with Cancer, Cardiovascular Disease, and Diabetes: A Systematic Review of the Epidemiological Evidence.

Authors:  Chin-Chi Kuo; Katherine A Moon; Shu-Li Wang; Ellen Silbergeld; Ana Navas-Acien
Journal:  Environ Health Perspect       Date:  2017-08-01       Impact factor: 9.031

10.  Seizure 6-like (SEZ6L) gene and risk for lung cancer.

Authors:  Ivan P Gorlov; Peter Meyer; Triantafillos Liloglou; Jonathan Myles; Melanie Barbara Boettger; Adrian Cassidy; Luc Girard; John D Minna; Reiner Fischer; Stephen Duffy; Margaret R Spitz; Karl Haeussinger; Stefan Kammerer; Charles Cantor; Rainer Dierkesmann; John K Field; Christopher I Amos
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

View more
  3 in total

1.  Temporal Modulation of Differential Alternative Splicing in HaCaT Human Keratinocyte Cell Line Chronically Exposed to Arsenic for up to 28 Wk.

Authors:  Ana P Ferragut Cardoso; Mayukh Banerjee; Laila Al-Eryani; Mohammed Sayed; Daniel W Wilkey; Michael L Merchant; Juw W Park; J Christopher States
Journal:  Environ Health Perspect       Date:  2022-01-24       Impact factor: 9.031

2.  LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia.

Authors:  Tingting Hu; Yingjie Zhang; Tianqing Yang; Qingnan He; Mingyi Zhao
Journal:  Front Genet       Date:  2022-03-11       Impact factor: 4.599

3.  Establishment and Validation of a Tumor Microenvironment Prognostic Model for Predicting Bladder Cancer Survival Status Based on Integrated Bioinformatics Analyses.

Authors:  Qiu Chen; Guicao Yin; Xingjun He; Tianlin Jiang; Haisen Zhou; Yunjiang Wu; Yifan Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-03       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.